<DOC>
	<DOCNO>NCT02573272</DOCNO>
	<brief_summary>Knowing impact use ESL adjunctive treatment partial epilepsy cardiovascular risk factor measure biochemical ultrasound parameter compare enzyme-inducing AEDs .</brief_summary>
	<brief_title>Impact Eslicarbazepine Acetate Lipid Metabolism Cardiovascular Risk Factors</brief_title>
	<detailed_description />
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Patients 18 year patient definitively diagnose Focal Epilepsy base clinical criterion additional test . patient stable identifiable antiepileptic treatment last two year . patient accord investigator able provide clinical data necessary development study Patients sign informed consent Patients , accord evolution demand clinical practice , previous treatment change reason breach inclusion criterion / attachment one study group .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>